Sign Out
Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (see Dosage & Administration and Pharmacology: Pharmacodynamics under Actions).
Powder for concentrate for solution for infusion: Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard therapy (see Pharmacology: Pharmacodynamics under Actions).
Solution for injection: Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy (see Pharmacology: Pharmacodynamics under Actions).
